Skip to content
10-K

Annual Report

Aclaris Therapeutics, Inc. ACRS

0001104659-26-020540

← back to feed
Filed
Feb 26, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Jan 30, 2026 120.6M sh
Shares Diluted FY 2025 · Dec 31, 2025 122.56M sh
Shares Diluted FY 2025 · Dec 31, 2024 77.3M sh
Capex FY 2025 · Dec 31, 2025 $111K
Capex FY 2025 · Dec 31, 2024 $121K
Operating Cash Flow FY 2025 · Dec 31, 2025 −$47.11M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$20.08M
Cash And Equivalents FY 2025 · Dec 31, 2025 $19.96M
Cash And Equivalents FY 2025 · Dec 31, 2024 $24.57M
Stockholders Equity FY 2025 · Dec 31, 2025 $103.08M
Stockholders Equity FY 2025 · Dec 31, 2024 $155.55M
Stockholders Equity FY 2025 · Dec 31, 2023 $157.18M
Current Liabilities FY 2025 · Dec 31, 2025 $28.65M
Current Liabilities FY 2025 · Dec 31, 2024 $31.6M
Total Liabilities FY 2025 · Dec 31, 2025 $57.38M
Total Liabilities FY 2025 · Dec 31, 2024 $64.77M
Current Assets FY 2025 · Dec 31, 2025 $96.32M
Current Assets FY 2025 · Dec 31, 2024 $125.95M
Total Assets FY 2025 · Dec 31, 2025 $160.46M
Total Assets FY 2025 · Dec 31, 2024 $220.33M
Eps Diluted FY 2025 · Dec 31, 2025 −$0.53
Eps Diluted FY 2025 · Dec 31, 2024 −$1.71
Eps Basic FY 2025 · Dec 31, 2025 −$0.53
Eps Basic FY 2025 · Dec 31, 2024 −$1.71
Sga Expense FY 2025 · Dec 31, 2025 $21.97M
Sga Expense FY 2025 · Dec 31, 2024 $22.2M
Rd Expense FY 2025 · Dec 31, 2025 $52.65M
Rd Expense FY 2025 · Dec 31, 2024 $33.59M
Net Income FY 2025 · Dec 31, 2025 −$64.92M
Net Income FY 2025 · Dec 31, 2024 −$132.07M
Operating Income FY 2025 · Dec 31, 2025 −$76.38M
Operating Income FY 2025 · Dec 31, 2024 −$141.93M
Cost Of Revenue FY 2025 · Dec 31, 2025 $2.09M
Cost Of Revenue FY 2025 · Dec 31, 2024 $2.79M
Revenue FY 2025 · Dec 31, 2025 $7.83M
Revenue FY 2025 · Dec 31, 2024 $18.72M